Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] How glucocorticoids change life in Duchenne muscular dystrophy

Chronic glucocorticoid treatment is well anchored in the standards of care for Duchenne muscular dystrophy and is supported by evidence of efficacy in short-term randomised controlled trials.1,2 In clinical practice, different compounds are prescribed in a range of doses and regimens and are most often tailored to the individual side-effect profile because there is a paucity of strong data to guide duration of treatment and regimen, with only non-randomised studies and retrospective studies showing evidence of functional benefit or effect on survival.